Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Hemangioendothelioma
- Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma
- Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
- Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
- Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
- Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
- SCMC Trial on KHE With KMP (V.2020)
- Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
- Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
- Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
- Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
- Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
- Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma
- Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
- Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.
- A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
- Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
- Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
- Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies